Kamran Alam, Chief Financial Officer at Taysha Gene Therapies, Inc. (TSHA), sold 33,000 shares at $2.33 ($77K) on 2023-08-24, disclosed to the SEC on 2023-08-25.
Scheduled sale ($77k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| TSHA | SELL | 2025-08-22 | $311K | — | Filing → |
| TSHA | SELL | 2022-08-24 | $12K | — | Filing → |
| TSHA | SELL | 2022-08-22 | $106K | — | Filing → |